Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).

@article{Arasth2012TwentyfourweekEA,
  title={Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).},
  author={Keikawus Arast{\'e}h and Doug Ward and Andreas Plettenberg and J. M. Livrozet and Chloe M. Orkin and Christiane Cordes and J Guo and Edward Wang and Chung Lip Yong and Patrick G. Robinson and A Quinson},
  journal={HIV medicine},
  year={2012},
  volume={13 4},
  pages={236-44}
}
OBJECTIVES Once-daily (qd) antiretroviral therapies improve convenience and adherence. If found to be effective, nevirapine extended release (NVP XR) will confer this benefit. The TRANxITION trial examined the efficacy and safety of switching virologically suppressed patients from NVP immediate release (NVP IR) 200 mg twice daily to NVP XR 400 mg qd. METHODS An open-label, parallel-group, noninferiority, randomized (2:1 NVP XR:NVP IR) study was performed. Adult HIV-1-infected patients… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
9 Citations
17 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Guidance for industry antiretroviral drugs using plasma HIV RNA measurements – clinical considerations for accelerated and traditional approval

  • W Cochran
  • 2002

Similar Papers

Loading similar papers…